With insurance company step-therapies and increasingly high copays it will become even more difficult to achieve LDA/remission in our RA patients. Physicians might also be less motivated to change treatment as disease management becomes overly complicated by multiple metrics, the 2015 ACR RA guidelines and the dreaded prior authorization process. Yet another obstacle is direct to consumer ads laden with long lists of horrible side-effects.